Oxford BioDynamics PLC Presents ALS signatures at NEALS
11 October 2017 - 5:00PM
RNS Non-Regulatory
TIDMOBD
Oxford BioDynamics PLC
11 October 2017
11 October 2017
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Oxford BioDynamics presents ALS signatures at NEALS
EpiSwitch(TM) signature is able to diagnose and successfully
predict disease progression
Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology
company focused on the discovery and development of epigenetic
biomarkers based on regulatory genome architecture for use within
the pharmaceutical and biotechnology industry, today announces that
its Senior Director, Dr Willem Westra, participated in an Industry
Partner Roundtable at the 2017 Annual Northeast ALS Consortium
(NEALS) Meeting in Florida and presented two distinct epigenetic
signatures for Amyotrophic Lateral Sclerosis (ALS) diagnosis and
prognosis.
The objective of the prospective study was to determine the
sensitivity and specificity of two epigenetic-based ALS disease
signatures for the diagnosis of ALS and for the prognosis of fast
versus slow progressing ALS. 100 patients' samples were compared to
controls at three and six months following the initial clinical
visit. During each visit, participants underwent the ALS-Functional
Rating Scale-Revised assessment, forced vital capacity tests, and
provided a blood sample that was analysed using EpiSwitch(TM).
A comparative interrogation of the genomic architecture from
healthy and diseased-patient blood samples revealed two unique
ALS-related epigenetic signatures: one with diagnostic potential
and a second for prognosis prediction. The diagnostic signature
reported specificity of 75% and sensitivity of 88% on the
validation cohort whilst the prognostic test reported sensitivity
and specificity of 80%.
Dr Alexandre Akoulitchev, Chief Scientific Officer of Oxford
BioDynamics, commented:
"We are delighted to present two distinct epigenetic signatures
for ALS diagnosis and prognosis at the Annual NEALS Meeting in
Florida. This prospective study has delivered two new and unique
epigenetic biomarker signatures that have the potential to improve
the time to diagnosis and provide a predictive prognosis for the
progression of the disease. We look forward to further expanding
our EpiSwitch(TM) ALS studies in close collaboration with leading
clinical experts, both in US and UK. Our aim is to contribute to
improvement in ALS patient care and to support ALS therapeutic
developments by improving diagnostic and prognostic patient
stratifications.
The EpiSwitch(TM) technology, which has already delivered highly
valuable stratification results for treatments in rheumatoid
arthritis and immuno-oncology, has now demonstrated its potential
in neurological conditions and has provided its first valuable
contribution into ALS for better disease understanding of patient
stratification. This is a result of many years of work for our
highly dedicated team and we are greatly inspired by these results
and look forward to future developments."
For further details contact:
Oxford BioDynamics Plc +44 (0)1865 518910
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO
Stifel Nicolaus Europe
Limited +44 (0)20 7710 7600
Nominated Advisor and
Broker
David Arch
Jonathan Senior
Peter Lees
Ben Maddison
Shore Capital +44 (0)20 7408 4090
Joint Broker
Stephane Auton
Edward Mansfield
FTI Consulting +44 (0)20 3727 1000
Financial Public Relations
Advisor
Julia Phillips
Brett Pollard
Natalie Garland-Collins
Anna Foster
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes, and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAMMBATMBABBLR
(END) Dow Jones Newswires
October 11, 2017 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024